BENDHEIM JACK 4
4 · PHIBRO ANIMAL HEALTH CORP · Filed Feb 18, 2026
Research Summary
AI-generated summary of this filing
Phibro (PAHC) 10% Owner Jack Bendheim Sells Shares
What Happened Jack Bendheim, a director/officer and reported 10% owner (via BFI Co., LLC), sold a total of 14,080 Phibro Animal Health (PAHC) shares in open-market transactions on Feb 13 and Feb 18, 2026. The sales break down as: 7,040 shares at a weighted average price of $51.96 for $365,822; 6,824 shares at a weighted average price of $51.38 for $350,599; and 216 shares at a weighted average price of $51.97 for $11,225 — aggregate proceeds ≈ $727,646. These transactions were sales (not purchases), and at least some were effected under a Rule 10b5-1 trading plan.
Key Details
- Dates and reported weighted-average prices:
- 2026-02-13: 7,040 shares @ $51.96 (total $365,822). Price range reported: $51.90–$52.05 (footnote).
- 2026-02-18: 6,824 shares @ $51.38 (total $350,599). Price range reported: $50.90–$51.875 (footnote).
- 2026-02-18: 216 shares @ $51.97 (total $11,225). Price range reported: $51.61–$52.345 (footnote).
- Aggregate sold: 14,080 shares for ≈ $727,646.
- Ownership after transaction: not specified in the filing (filing does not state total shares held post-sale).
- Notable footnotes:
- Sales were effected pursuant to a Rule 10b5-1 plan adopted by BFI Co., LLC (May 30, 2025).
- Some reported securities are directly held by BFI; Jack Bendheim exercises voting/dispositive power over BFI and disclaims beneficial ownership except to his pecuniary interest. At least some shares are directly held by Mr. Bendheim.
- Reported prices are weighted averages; the filing offers to provide a breakdown of the number of shares sold at each separate price on request.
- Filing timeliness: report filed Feb 18, 2026 covering trades on Feb 13 and Feb 18; the filing itself does not mark a late report.
Context
- These are routine sales by a significant owner and include transactions executed under a pre-established 10b5-1 plan, which typically schedules sales in advance and can reduce signals about timing or intent. For retail investors, purchases by insiders tend to be more informative than sales; these sales alone do not indicate company fundamentals.
Insider Transaction Report
Form 4
BENDHEIM JACK
DirectorPresident and CEO10% Owner
Transactions
- Sale
Class A Common Stock
[F1][F2][F3]2026-02-13$51.96/sh−7,040$365,822→ 43,720 total(indirect: See) - Sale
Class A Common Stock
[F1][F4][F3]2026-02-18$51.38/sh−6,824$350,599→ 36,896 total(indirect: See) - Sale
Class A Common Stock
[F1][F5][F3]2026-02-18$51.97/sh−216$11,225→ 36,680 total(indirect: See)
Holdings
- 16,840
Class A Common Stock
[F6]
Footnotes (6)
- [F1]The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.61 to $52.345. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 and 5.
- [F3]The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.90 to $51.875.
- [F5]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.90 to $52.05.
- [F6]The reported securities are directly held by Jack Bendheim.